Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hypersensitivity Reaction

Free Subscription Articles published in Br J Dermatol Retrieve available abstracts of 90 articles: HTML format

Single Articles

September 2025
1. AFTAB Y, Moloney S, Ho B, Raymond B, et al
   Four decades of stagnation: A qualitative exploration of the lived experience of Atopic Dermatitis across ethnically and sexually diverse adults in the United Kingdom.
   Br J Dermatol. 2025 Sep 26:ljaf377. doi: 10.1093.
   PubMed    
   
   
   
2. WANG SP, Myers E, Arents BWM, Flohr C, et al
   Caution regarding interpretation of trends for the global burden of atopic dermatitis and asthma.
   Br J Dermatol. 2025 Sep 26:ljaf369. doi: 10.1093.
   PubMed    
   
   
   
3. YIU ZZN
   Previous ineligibility for or treatment failure of ciclosporin does not influence lebrikizumab efficacy in atopic dermatitis.
   Br J Dermatol. 2025 Sep 23:ljaf316. doi: 10.1093.
   PubMed    
   
   
   
4. WARREN RB, de Bruin-Weller M, Tsianakas A, Khemis A, et al
   Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).
   Br J Dermatol. 2025 Sep 22:ljaf285. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. ZHANG L, Wang M, Zhang L, Liang Y, et al
   Efficacy and Safety of Pumecitinib Gel for Treating Mild-to-moderate Atopic Dermatitis: a Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Phase IIb Clinical Trial.
   Br J Dermatol. 2025 Sep 18:ljaf363. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. ZHANG J, Silverberg JI, Guo J, Yun J, et al
   Rademikibart monotherapy for moderate-to-severe atopic dermatitis in a 1-year, randomized, phase II trial (SEASIDE CHINA): initial two-week dosing, followed by two-week or four-week dosing.
   Br J Dermatol. 2025 Sep 2:ljaf347. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2025
7. OLESEN CM, Agner T
   Can food allergy be prevented by handwashing?
   Br J Dermatol. 2025 Aug 30:ljaf283. doi: 10.1093.
   PubMed    
   
   
   
8. REICH K, Langley RG, Salvador JFS, Staumont-Salle D, et al
   Safety of tralokinumab in patients with moderate-to-severe atopic dermatitis followed for up to 4.5 years: an integrated analysis of 8 clinical trials.
   Br J Dermatol. 2025 Aug 29:ljaf309. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. BABER C, Busch L, Klein AL, Infante VHP, et al
   Mechanistic in vivo studies of secondary skin-to-skin peanut allergen transfer to determine the impact of hand washing in reducing the risk of cutaneous sensitization.
   Br J Dermatol. 2025 Aug 16:ljaf214. doi: 10.1093.
   PubMed     Abstract available
   
   
   June 2025
10. KRISTYANTO H, Rey Torre S, Cunney A, Dunder K, et al
    The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis.
    Br J Dermatol. 2025 Jun 28:ljaf259. doi: 10.1093.
    PubMed    
    
    
    
11. SEXTON F, O' Mahony J, Sumera S, Golchin R, et al
    Culprit allergens in diabetes technology-associated allergic contact dermatitis: investigation remains challenging.
    Br J Dermatol. 2025 Jun 26:ljaf245. doi: 10.1093.
    PubMed    
    
    
    
12. LEE EY, Ang YS, Leow SY, Koh MJA, et al
    Mobile Inpatient Care at Home: A Pilot Programme for Paediatric Patients with Atopic Dermatitis in Singapore.
    Br J Dermatol. 2025 Jun 24:ljaf246. doi: 10.1093.
    PubMed    
    
    
    
13. GOODERHAM M, Torres T, Imafuku S, Rademaker M, et al
    Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up).
    Br J Dermatol. 2025 Jun 23:ljaf236. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. O'REILLY P, Savarimalai R, Walsh S, Barry LA, et al
    The impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on the health-related quality of life (HRQoL) experiences of adults with SJS/TEN: A mixed method systematic review.
    Br J Dermatol. 2025 Jun 21:ljaf229. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. CHANG CY, Chan K, Chen HC, Lai CC, et al
    Atopic dermatitis epidemiological research methodology: a global scoping review.
    Br J Dermatol. 2025 Jun 19:ljaf238. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
16. BRUSTAD N, Wang T, Chen L, Kaiser H, et al
    Prenatal high-dose vitamin D supplementation and childhood atopic dermatitis until age 6 years: A secondary analysis of a randomized clinical trial.
    Br J Dermatol. 2025 May 30:ljaf208. doi: 10.1093.
    PubMed    
    
    
    
17. ANDREW PV, Williams SF, Brown K, Chittock J, et al
    Topical supplementation with physiologic lipids rebalances the stratum corneum ceramide profile and strengthens skin barrier function in adults predisposed to atopic dermatitis.
    Br J Dermatol. 2025 May 23:ljaf200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. DRUCKER AM, Walwyn C, Chu C, Yiu ZZN, et al
    Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis.
    Br J Dermatol. 2025 May 7:ljaf166. doi: 10.1093.
    PubMed    
    
    
    
19. KIRCIK L, Tsianakas A, Valenzuela F, Mikol V, et al
    Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial.
    Br J Dermatol. 2025 May 3:ljaf156. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. GILLESPIE J, Bash GN, Jacobson ME, Latour E, et al
    Harmonizing Measurement of Eczema Control- Mapping Scores Between the Atopic Dermatitis Control Tool and The Recap of Atopic Eczema Instrument.
    Br J Dermatol. 2025 May 2:ljaf167. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
21. SILVERBERG JI, Dodiuk-Gad R, Takaoka R, Tan J, et al
    Atopic dermatitis starting in childhood has a stronger impact on adults: results from the "Scars of Life" international project in 27 countries.
    Br J Dermatol. 2025 Apr 26:ljaf158. doi: 10.1093.
    PubMed    
    
    
    
22. LEMARCQ L, Reynaert V, Van den Steen E, Evers-Lebrun C, et al
    Outcome Measures for Interdisciplinary Care in Immune-mediated Inflammatory Skin Diseases (skIMIDs): A Scoping Review.
    Br J Dermatol. 2025 Apr 18:ljaf153. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. ZHU J, Abuabara K
    Complex comorbidities: Could a diabetes drug help prevent atopic dermatitis?
    Br J Dermatol. 2025 Apr 15:ljaf131. doi: 10.1093.
    PubMed    
    
    
    
24. HENDERSON D, Turner PJ, Hourihane JO
    Isotretinoin and peanut allergy: evidence of safety is staring us in the face.
    Br J Dermatol. 2025 Apr 15:ljaf137. doi: 10.1093.
    PubMed    
    
    
    
25. TRAN V, Wong C, Belobrov S, De Cruz R, et al
    Orofacial granulomatosis secondary to sodium metabisulfite contact allergy.
    Br J Dermatol. 2025 Apr 9:ljaf132. doi: 10.1093.
    PubMed    
    
    
    March 2025
26. ALEXANDER H, Murryam S, Kezic S, Motazedi E, et al
    Methotrexate and Cyclosporin Improve Skin Biomarkers in Paediatric Atopic Dermatitis: Results from the TREatment of Severe Atopic Eczema Trial.
    Br J Dermatol. 2025 Mar 27:ljaf115. doi: 10.1093.
    PubMed    
    
    
    
27. VESTERGAARD C
    Air Pollution and Atopic Dermatitis: Critical Windows of Risk in Early Life.
    Br J Dermatol. 2025 Mar 24:ljaf109. doi: 10.1093.
    PubMed    
    
    
    
28. NAKAMIZO S, Kabashima K
    Cutaneous Granulomas: Mechanisms, Cellular Interactions, and Therapeutic Insights.
    Br J Dermatol. 2025 Mar 13:ljaf096. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. LI T, Tao R, Yang L, Wan Z, et al
    Upadacitinib outperforms dupilumab in restoring the fungal microbiome in atopic dermatitis.
    Br J Dermatol. 2025 Mar 12:ljaf095. doi: 10.1093.
    PubMed    
    
    
    
30. WEN YL, Hsu WT, Chen YH, Kao HH, et al
    Sodium-glucose Cotransporter 2 Inhibitors and Inverse Risk of New-onset Atopic Dermatitis in Diabetic Population: a Nationwide, Active-comparator Study.
    Br J Dermatol. 2025 Mar 4:ljaf086. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
31. LIN LH, Lee CC, Hwang MM, Jung CR, et al
    Fine particulate matter exposure and incident atopic dermatitis: A birth cohort study.
    Br J Dermatol. 2025 Feb 26:ljaf075. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. SZONDI DC, Crompton RA, Oon L, Subramaniam N, et al
    A role for Arginase in skin epithelial differentiation and anti-microbial peptide production.
    Br J Dermatol. 2025 Feb 14:ljaf057. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. VON KOBYLETZKI L, Svensson A
    Patient-reported outcome measures are highly needed for patients with skin of colour with atopic dermatitis.
    Br J Dermatol. 2025 Feb 4:ljaf043. doi: 10.1093.
    PubMed    
    
    
    January 2025
34. LEDUCQ S, Fong WCG, Williams HC, Bradshaw L, et al
    Reporting of concomitant and rescue topical therapies in atopic dermatitis randomised controlled trials evaluating a systemic treatment: a scoping review.
    Br J Dermatol. 2025 Jan 30:ljaf031. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. ALVES C
    Orismilast for moderate-to-severe atopic dermatitis: the potential therapeutic value of a new oral pharmacological alternative.
    Br J Dermatol. 2025 Jan 30:ljaf042. doi: 10.1093.
    PubMed    
    
    
    
36. HARTFORD C, Alexis A, Wang Z, Levit NA, et al
    Development of novel patient-reported outcome instruments to assess atopic dermatitis-associated dyspigmentation and xerosis in patients with skin of colour.
    Br J Dermatol. 2025 Jan 10:ljae494. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. SILVERBERG JI, Eichenfield LF, Blauvelt A, Irvine AD, et al
    Orismilast, a PDE4B/D inhibitor, in moderate-to-severe atopic dermatitis: Efficacy and safety from a multicenter, randomized, placebo-controlled, phase 2b dose-ranging study (ADESOS).
    Br J Dermatol. 2025 Jan 7:ljae507. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2024
38. CARRASCOSA JM
    Optimizing dosing in atopic dermatitis therapy: Looking for the cream of the crop.
    Br J Dermatol. 2024 Dec 25:ljae514. doi: 10.1093.
    PubMed    
    
    
    
39. MORTATO E, Talamonti M, Paganini C, Belcastro A, et al
    Comment on "A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council"- A case of Rhabdomyolysis Induced by Upadacitinib.
    Br J Dermatol. 2024 Dec 13:ljae485. doi: 10.1093.
    PubMed    
    
    
    
40. CHO SI, Na JI
    Long-term observation to determine durable efficacy and safety of novel paediatric atopic dermatitis treatment, nemolizumab.
    Br J Dermatol. 2024 Dec 10:ljae479. doi: 10.1093.
    PubMed    
    
    
    
41. WEIDINGER S, Bewley A, Hong HC, Silvestre JF, et al
    Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2024 Dec 5:ljae439. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2024
42. IGARASHI A, Katsunuma T, Nagano Y, Komazaki H, et al
    Long-term (68 weeks) administration of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: efficacy and safety data from a phase III study.
    Br J Dermatol. 2024 Nov 28:ljae458. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. CHIU TM, Chen CB, Lu CW, Hui RC, et al
    CCR8/CCL1 and CXCR3/CXCL10 axis mediated memory T cell activations in recalcitrant drug-induced hypersensitivity patients.
    Br J Dermatol. 2024 Nov 6:ljae375. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
44. KATOH N, Tanaka A, Takahashi H, Shimizu R, et al
    Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week, randomized, double-blind, placebo-controlled phase III trial in Japan (ADhere-J).
    Br J Dermatol. 2024 Oct 23:ljae394. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. SILVERBERG JI, Bunick CG, Hong HC, Mendes-Bastos P, et al
    Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up).
    Br J Dermatol. 2024 Oct 23:ljae404. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. BARBIERI JS
    Levelling up outcomes in atopic dermatitis through personalized dosing of upadacitinib.
    Br J Dermatol. 2024 Oct 19:ljae410. doi: 10.1093.
    PubMed    
    
    
    
47. KOBYLETZKI LBV, Svensson A
    Treatment for atopic dermatitis with JAK Inhibitors-useful recommendations from expert opinions.
    Br J Dermatol. 2024 Oct 19:ljae396. doi: 10.1093.
    PubMed    
    
    
    
48. SORENSEN SBT, Farkas DK, Vestergaard C, Schmidt SAJ, et al
    Urticaria and the risk of cancer: a Danish population-based cohort study.
    Br J Dermatol. 2024;191:706-712.
    PubMed     Abstract available
    
    
    
49. BETTUZZI T, Welfringer-Morin A, Ingen-Housz-Oro S, Bataille P, et al
    Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study.
    Br J Dermatol. 2024;191:698-705.
    PubMed     Abstract available
    
    
    
50. KUMARI R, Apfelbacher CJ, Nelson-Piercy C, Flohr C, et al
    The management of atopic dermatitis in women of childbearing age: confused terminology, lack of evidence and resulting clinical inertia.
    Br J Dermatol. 2024 Oct 12:ljae398. doi: 10.1093.
    PubMed    
    
    
    
51. BLAUVELT A, Reckleff J, Zhao Y, Clark M, et al
    Content Evaluation of Pruritus, Skin Pain, and Sleep Disturbance Patient-Reported Outcome Measures in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: Qualitative Interviews.
    Br J Dermatol. 2024 Oct 4:ljae346. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2024
52. HUBENTHAL M, Dai C, Brown SJ, Heinrich L, et al
    Mapping SCORing of Atopic Dermatitis (SCORAD) and objective SCORAD to the Eczema Area and Severity Index to facilitate large-scale meta-analyses of molecular data.
    Br J Dermatol. 2024;191:637-639.
    PubMed    
    
    
    
53. HAAG C, Alexis A, Aoki V, Bissonnette R, et al
    A Practical Guide to Using Oral JAK Inhibitors for Atopic Dermatitis from the International Eczema Council.
    Br J Dermatol. 2024 Sep 10:ljae342. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. ARDERN-JONES MR, Brown SJ, Flohr C, Hossain P, et al
    An expert consensus on managing dupilumab-related ocular surface disorders in people with atopic dermatitis 2024.
    Br J Dermatol. 2024 Sep 5:ljae344. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
55. GIPPLE MO, Dhami RK, Latour E, Keller JJ, et al
    Morgellons disease shows a lower quality of life than psoriasis, atopic dermatitis, and prurigo nodularis.
    Br J Dermatol. 2024 Aug 21:ljae335. doi: 10.1093.
    PubMed    
    
    
    
56. SERVATTALAB SE, Lee M, Hlobik M, Song H, et al
    Examining racial and ethnic disparities in diagnosis and access to care in infantile atopic dermatitis in the United States: a retrospective cohort study.
    Br J Dermatol. 2024 Aug 20:ljae322. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. O'REILLY P, Walsh S, Bunker CB, Ryan S, et al
    The quality-of-life impact of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) on patients' lives: An interpretative descriptive qualitative study.
    Br J Dermatol. 2024 Aug 20:ljae334. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. KPENOU FC, Paul C, Seneschal J, Andreu N, et al
    The Atopic Dermatitis Patient Journey: Insights from a Qualitative Study.
    Br J Dermatol. 2024 Aug 18:ljae329. doi: 10.1093.
    PubMed    
    
    
    
59. DEKKERS C, de Bruin-Weller M
    The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis.
    Br J Dermatol. 2024;191:316-317.
    PubMed    
    
    
    
60. HAMA N, Aoki S, Chen CB, Hasegawa A, et al
    Recent progress of Stevens-Johnson syndrome/toxic epidermal necrolysis: Diagnosis criteria, pathogenesis and therapy.
    Br J Dermatol. 2024 Aug 14:ljae321. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2024
61. ALEXANDER H, Malek R, Prieto-Merino D, Gribaleva E, et al
    A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
    Br J Dermatol. 2024 Jul 24:ljae287. doi: 10.1093.
    PubMed     Abstract available
    
    
    
62. GRATTAN CEH, Kocaturk E
    How relevant are eosinophils to chronic spontaneous urticaria? No evidence of clinical benefit from eosinophil depletion with benralizumab.
    Br J Dermatol. 2024;191:153-154.
    PubMed    
    
    
    
63. ALTRICHTER S, Gimenez-Arnau AM, Bernstein JA, Metz M, et al
    Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial.
    Br J Dermatol. 2024;191:187-199.
    PubMed     Abstract available
    
    
    
64. BRUCE G, Rosala-Hallas A, Jones AP, Turner C, et al
    The effects of ciclosporin and methotrexate on kidney function in the treatment of severe atopic dermatitis in children - results from the TREAT trial.
    Br J Dermatol. 2024 Jul 15:ljae276. doi: 10.1093.
    PubMed    
    
    
    
65. BERTLICH M, Hartmann D, Freytag S, French LE, et al
    Sensitization against medical hyaluronidase in patients with confirmed hypersensitivity against hymenoptera species and its clinical implications.
    Br J Dermatol. 2024 Jul 15:ljae290. doi: 10.1093.
    PubMed     Abstract available
    
    
    
66. LI A, Musters AH, Hyseni A, Gerbens LAA, et al
    Dupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-center cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
    Br J Dermatol. 2024 Jul 15:ljae289. doi: 10.1093.
    PubMed    
    
    
    
67. JIA Q, Cao Q, Peng C, Shui X, et al
    Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study.
    Br J Dermatol. 2024 Jul 2:ljae278. doi: 10.1093.
    PubMed    
    
    
    June 2024
68. HAGENSTROM K, Klinger T, Muller K, Willers C, et al
    Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis.
    Br J Dermatol. 2024 Jun 27:ljae250. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. DANBY SG
    Debunking the myth that all emollients are equal opens the door for future atopic dermatitis prevention studies.
    Br J Dermatol. 2024;191:6-7.
    PubMed    
    
    
    
70. BARBAROT S, Aubert H, Vibet MA, Leray M, et al
    Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial.
    Br J Dermatol. 2024 Jun 12:ljae111. doi: 10.1093.
    PubMed     Abstract available
    
    
    
71. GUTTMAN-YASSKY E, Croft M, Geng B, Rynkiewicz N, et al
    The role of OX40L/OX40 axis signalling in atopic dermatitis.
    Br J Dermatol. 2024 Jun 5:ljae230. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
72. 
    Contact allergies to dental material.
    Br J Dermatol. 2024;190:e66.
    PubMed    
    
    
    
73. 
    The impact of atopic dermatitis on children and adolescents.
    Br J Dermatol. 2024;190:e65.
    PubMed    
    
    
    
74. GREKOWITZ E, Metz M, Altrichter S, Bauer A, et al
    Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
    Br J Dermatol. 2024;190:825-835.
    PubMed     Abstract available
    
    
    
75. RAGAMIN A, Zhang J, Pasmans SGMA, Schappin R, et al
    The construct validity, responsiveness, reliability and interpretability of the Recap of atopic eczema questionnaire (RECAP) in children.
    Br J Dermatol. 2024;190:867-875.
    PubMed     Abstract available
    
    
    
76. CHIESA FUXENCH ZC
    The burden of atopic dermatitis across paediatric populations: 'it's not just an itch that rashes'.
    Br J Dermatol. 2024;190:783-784.
    PubMed    
    
    
    April 2024
77. HALIOUA B, Skayem C, Merhand S, Ben Hayoun Y, et al
    Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis.
    Br J Dermatol. 2024 Apr 29:ljae176. doi: 10.1093.
    PubMed    
    
    
    
78. PHILLIPS C, Russell E, McNiven A, McPherson T, et al
    A Qualitative Study of the Psychological Morbidity in Paediatric Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
    Br J Dermatol. 2024 Apr 12:ljae154. doi: 10.1093.
    PubMed    
    
    
    
79. SIMPSON EL, Eckert L, Gadkari A, Brown TM, et al
    Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
    Br J Dermatol. 2024 Apr 9:ljae056. doi: 10.1093.
    PubMed    
    
    
    March 2024
80. SANDER N, Stolzl D, Fonfara M, Hartmann J, et al
    Blockade of IL-13 signaling improves skin barrier function and biology in patients with moderate to severe atopic dermatitis.
    Br J Dermatol. 2024 Mar 26:ljae138. doi: 10.1093.
    PubMed     Abstract available
    
    
    
81. BENTZ P, Weisshaar E
    Biomarkers as key concepts in managing atopic dermatitis and psoriasis: Unlocking new ways of care for patient suffering from chronic hand dermatoses.
    Br J Dermatol. 2024 Mar 26:ljae127. doi: 10.1093.
    PubMed    
    
    
    
82. 
    Correction to: Circulating biomarkers are associated with disease severity of chronic hand eczema and atopic dermatitis.
    Br J Dermatol. 2024 Mar 22:ljae112. doi: 10.1093.
    PubMed    
    
    
    
83. 
    The relationship between paediatric eczema and cognition.
    Br J Dermatol. 2024;190:e41.
    PubMed    
    
    
    
84. 
    A guide to using the core outcome set for eczema.
    Br J Dermatol. 2024;190:e44.
    PubMed    
    
    
    
85. NIELSEN W, Drucker AM
    The need and benefit of the Harmonising Outcome Measures for Eczema user's guide.
    Br J Dermatol. 2024;190:462-463.
    PubMed    
    
    
    
86. 
    Correction to: Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2024 Mar 12:ljae093. doi: 10.1093.
    PubMed    
    
    
    
87. CHEN GF, Xu S, White MA, Cohen JM, et al
    Association between atopic dermatitis and eating disorders: a cross-sectional study in the All of Us Research Program.
    Br J Dermatol. 2024 Mar 11:ljae103. doi: 10.1093.
    PubMed    
    
    
    
88. REHBINDER EM, Warnberg Gerdin S, Hoyer A, Bradley M, et al
    Frequent oil-baths and skin barrier during infancy in the PreventADALL study.
    Br J Dermatol. 2024 Mar 6:ljae091. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
89. RAMESSUR R, Dand N, Langan SM, Saklatvala J, et al
    Defining disease severity in atopic dermatitis and psoriasis for the application to biomarker research- an inter-disciplinary perspective.
    Br J Dermatol. 2024 Feb 29:ljae080. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2023
90. ISKANDAR IYK, Gawkrodger DJ, Gittins M, Byrne L, et al
    Trends in occupational and work-related contact dermatitis attributed to nickel, chromium and cobalt in the UK: findings from The Health and Occupation Research network 1996-2019.
    Br J Dermatol. 2023 Dec 7:ljad488. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.